ProbeChem®
*Expedite Your Scientific Research*

WWW.PROBECHEM.COM

# Data Sheet

Global Supplier of Chemical Probes, Inhibitors & Agonists.

| | | |
|---|---|---|
| **Product Name** | : | Lumiracoxib |
| **Cat. No.** | : | PC-20195 |
| **CAS No.** | : | 220991-20-8 |
| **Molecular Formula** | : | $C_{15}H_{13}ClFNO_2$ |
| **Molecular Weight** | : | 293.72 |
| **Target** | : | Cyclooxygenase (COX) |
| **Solubility** | : | 10 mM in DMSO |




## Biological Activity

Lumiracoxib (COX-189) is a highly selective **COX-2** inhibitor with IC50 of 0.14 uM in COX-2-expressing dermal fibroblasts, inhibits purified COX-2 with Ki of 0.06 uM, 50-fold selectivity over COX-1 (Ki=3 uM).
Lumiracoxib shows no inhibition of COX-1 at concentrations up to 30 microM (HEK 293 cells transfected with human COX-1).
Lumiracoxib shows IC50 of 0.13 uM a human whole blood assay, 515 fold over COX-1.
Ex vivo, lumiracoxib inhibited COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch with an ID(50) value of 0.24 mg kg(-1).
Lumiracoxib showed dose-dependent effect in rat models of hyperalgesia, oedema, pyresis and arthritis.

## References

Ronald Esser, et al. ***Br J Pharmacol***. 2005 Feb;144(4):538-50.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com